{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:04:28Z","timestamp":1791428668365,"version":"4.3.3"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["SFB54-P04"],"award-info":[{"award-number":["SFB54-P04"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The effect of conventional anti-platelet agents is limited in secondary stroke prevention, and their effects are blunted under high shear stress in the presence of increased levels of circulating von Willebrand factor (VWF). VWF is critically involved in thrombus formation at sites of stenotic extracranial\/intracranial arteries. A third generation anti-VWF aptamer (BT200) has been generated which could be useful for secondary stroke prevention. To characterize the effects of BT200 in blood of patients with large artery atherosclerosis stroke (LAA). Blood samples were obtained from 33 patients with acute stroke or transient ischemic attack to measure inhibition of VWF activity and VWF-dependent platelet function. Patients who received clopidogrel or dual antiplatelet therapy did not differ in VWF dependent platelet function tests from aspirin treated patients. Of 18 patients receiving clopidogrel with or without aspirin, only 3 had a prolonged collagen adenosine diphosphate closure time, and none of the patients had ristocetin induced aggregation in the target range. BT200 concentration-dependently reduced median VWF activity from 178 to &lt;\u20093%, ristocetin induced platelet aggregation from 40U to\u2009&lt;\u200910U and prolonged collagen adenosine diphosphate closure times from 93\u00a0s to\u2009&gt;\u2009300\u00a0s. Baseline VWF activity correlated (r\u2009=\u20090.86, p\u2009&lt;\u20090.001) with concentrations needed to reduce VWF activity to\u2009&lt;\u200920% of normal, indicating that BT200 acts in a target concentration-dependent manner. Together with a long half-life supporting once weekly administration, the safety and tolerability observed in an ongoing phase I trial, and the existence of a reversal agent, BT200 is an interesting drug candidate.<\/jats:p>","DOI":"10.1038\/s41598-021-82747-7","type":"journal-article","created":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T11:08:10Z","timestamp":1612436890000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["The aptamer BT200 blocks von Willebrand factor and platelet function in blood of stroke patients"],"prefix":"10.1038","volume":"11","author":[{"given":"Katarina D.","family":"Kovacevic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Greisenegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Langer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Gelbenegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Buchtele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Pabinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Petroczi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Jilma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,4]]},"reference":[{"key":"82747_CR1","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","volume":"139","author":"EJ Benjamin","year":"2019","unstructured":"Benjamin, E. J. et al. Heart disease and stroke statistics-2019 update: A report from the American Heart Association. Circulation 139, e56\u2013e528 (2019).","journal-title":"Circulation"},{"key":"82747_CR2","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1161\/CIRCRESAHA.116.308413","volume":"120","author":"VL Feigin","year":"2017","unstructured":"Feigin, V. L., Norrving, B. & Mensah, G. A. Global burden of stroke. Circ. Res. 120, 439\u2013448 (2017).","journal-title":"Circ. Res."},{"key":"82747_CR3","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7326\/0003-4819-105-6-825","volume":"105","author":"RJ Duke","year":"1986","unstructured":"Duke, R. J., Bloch, R. F., Turpie, A. G., Trebilcock, R. & Bayer, N. Intravenous heparin for the prevention of stroke progression in acute partial stable stroke. Ann. Intern. Med. 105, 825\u2013828 (1986).","journal-title":"Ann. Intern. Med."},{"key":"82747_CR4","doi-asserted-by":"crossref","unstructured":"The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet 349, 1569\u20131581 (1997).","DOI":"10.1016\/S0140-6736(97)04011-7"},{"key":"82747_CR5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1161\/STROKEAHA.106.476648","volume":"39","author":"HP Adams Jr","year":"2008","unstructured":"Adams, H. P. Jr. et al. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: Results of an international phase III trial: Abciximab in emergency treatment of stroke trial (AbESTT-II). Stroke 39, 87\u201399 (2008).","journal-title":"Stroke"},{"key":"82747_CR6","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1161\/STROKEAHA.111.000502","volume":"44","author":"L Kellert","year":"2013","unstructured":"Kellert, L. et al. Endovascular stroke therapy: Tirofiban is associated with risk of fatal intracerebral hemorrhage and poor outcome. Stroke 44, 1453\u20131455 (2013).","journal-title":"Stroke"},{"key":"82747_CR7","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1161\/STROKEAHA.110.599662","volume":"42","author":"M Siebler","year":"2011","unstructured":"Siebler, M. et al. Safety of tirofiban in acute Ischemic Stroke: The SaTIS trial. Stroke 42, 2388\u20132392 (2011).","journal-title":"Stroke"},{"key":"82747_CR8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1159\/000138337","volume":"26","author":"VL Serebruany","year":"2008","unstructured":"Serebruany, V. L., Alberts, M. J. & Hanley, D. F. Prasugrel in the poststroke cohort of the TRITON Trial: The clear and present danger. Cerebrovasc. Dis. 26, 93\u201394 (2008).","journal-title":"Cerebrovasc. Dis."},{"key":"82747_CR9","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1161\/STROKEAHA.111.000433","volume":"44","author":"DA Morrow","year":"2013","unstructured":"Morrow, D. A. et al. Efficacy and safety of vorapaxar in patients with prior ischemic stroke. Stroke 44, 691\u2013698 (2013).","journal-title":"Stroke"},{"key":"82747_CR10","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1111\/jth.14755","volume":"18","author":"S Zhu","year":"2020","unstructured":"Zhu, S. et al. The development and characterization of a long acting anti-thrombotic von Willebrand factor (VWF) aptamer. J. Thromb. Haemostas. JTH 18, 1113\u20131123 (2020).","journal-title":"J. Thromb. Haemostas. JTH"},{"issue":"Suppl 5","key":"82747_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1365-2516.2008.01848.x","volume":"14","author":"AJ Reininger","year":"2008","unstructured":"Reininger, A. J. Function of von Willebrand factor in haemostasis and thrombosis. Haemophilia 14(Suppl 5), 11\u201326 (2008).","journal-title":"Haemophilia"},{"key":"82747_CR12","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S0049-3848(00)00326-1","volume":"100","author":"M Li","year":"2000","unstructured":"Li, M. et al. Enhanced shear-induced von Willebrand factor binding to platelets in acute myocardial infarction. Thromb. Res. 100, 251\u2013261 (2000).","journal-title":"Thromb. Res."},{"key":"82747_CR13","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1096\/fasebj.7.2.8440408","volume":"7","author":"ZM Ruggeri","year":"1993","unstructured":"Ruggeri, Z. M. & von Ware, J. Willebrand factor. FASEB J. 7, 308\u2013316 (1993).","journal-title":"FASEB J."},{"key":"82747_CR14","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1182\/blood-2005-02-0618","volume":"107","author":"AJ Reininger","year":"2006","unstructured":"Reininger, A. J. et al. Mechanism of platelet adhesion to von Willebrand factor and microparticle formation under high shear stress. Blood 107, 3537\u20133545 (2006).","journal-title":"Blood"},{"key":"82747_CR15","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1161\/STROKEAHA.118.022888","volume":"49","author":"TA Fasipe","year":"2018","unstructured":"Fasipe, T. A. et al. Extracellular Vimentin\/VWF (von Willebrand factor) interaction contributes to VWF string formation and stroke pathology. Stroke 49, 2536\u20132540 (2018).","journal-title":"Stroke"},{"key":"82747_CR16","doi-asserted-by":"publisher","first-page":"E17","DOI":"10.1016\/j.ahj.2003.11.003","volume":"147","author":"U Derhaschnig","year":"2004","unstructured":"Derhaschnig, U., Pachinger, C. & Jilma, B. Variable inhibition of high-shear-induced platelet plug formation by eptifibatide and tirofiban under conditions of platelet activation and high von Willebrand release: A randomized, placebo-controlled, clinical trial. Am. Heart J. 147, E17 (2004).","journal-title":"Am. Heart J."},{"key":"82747_CR17","doi-asserted-by":"publisher","first-page":"4594","DOI":"10.1182\/blood-2002-11-3566","volume":"102","author":"RA Reiter","year":"2003","unstructured":"Reiter, R. A. et al. Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb\/IIIa inhibitors and aspirin. Blood 102, 4594\u20134599 (2003).","journal-title":"Blood"},{"key":"82747_CR18","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1042\/CS20120194","volume":"123","author":"AO Spiel","year":"2012","unstructured":"Spiel, A. O. et al. Effects of prasugrel on platelet inhibition during systemic endotoxaemia: A randomized controlled trial. Clin. Sci. 123, 591\u2013600 (2012).","journal-title":"Clin. Sci."},{"key":"82747_CR19","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1161\/STROKEAHA.111.628867","volume":"43","author":"SF De Meyer","year":"2012","unstructured":"De Meyer, S. F., Stoll, G., Wagner, D. D. & von Kleinschnitz, C. Willebrand factor: An emerging target in stroke therapy. Stroke 43, 599\u2013606 (2012).","journal-title":"Stroke"},{"key":"82747_CR20","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1161\/STROKEAHA.116.015677","volume":"48","author":"SR Williams","year":"2017","unstructured":"Williams, S. R. et al. Genetic drivers of von Willebrand factor levels in an ischemic stroke population and association with risk for recurrent stroke. Stroke 48, 1444\u20131450 (2017).","journal-title":"Stroke"},{"key":"82747_CR21","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1161\/STROKEAHA.106.474569","volume":"38","author":"AM Carter","year":"2007","unstructured":"Carter, A. M., Catto, A. J., Mansfield, M. W., Bamford, J. M. & Grant, P. J. Predictive variables for mortality after acute ischemic stroke. Stroke 38, 1873\u20131880 (2007).","journal-title":"Stroke"},{"key":"82747_CR22","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1161\/STROKEAHA.114.007624","volume":"46","author":"S Greisenegger","year":"2015","unstructured":"Greisenegger, S. et al. Biomarkers and mortality after transient ischemic attack and minor ischemic stroke. Stroke 46, 659\u2013666 (2015).","journal-title":"Stroke"},{"key":"82747_CR23","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1067\/mlc.2001.117406","volume":"138","author":"B Jilma","year":"2001","unstructured":"Jilma, B. Platelet function analyzer (PFA-100): A tool to quantify congenital or acquired platelet dysfunction. J. Lab. Clin. Med. 138, 152\u2013163 (2001).","journal-title":"J. Lab. Clin. Med."},{"key":"82747_CR24","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1160\/TH06-05-0242","volume":"96","author":"O Toth","year":"2006","unstructured":"Toth, O., Calatzis, A., Penz, S., Losonczy, H. & Siess, W. Multiple electrode aggregometry: A new device to measure platelet aggregation in whole blood. Thromb. Haemost. 96, 781\u2013788 (2006).","journal-title":"Thromb. Haemost."},{"key":"82747_CR25","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1160\/TH17-02-0129","volume":"117","author":"DE Schmidt","year":"2017","unstructured":"Schmidt, D. E. et al. Whole blood ristocetin-activated platelet impedance aggregometry (Multiplate) for the rapid detection of Von Willebrand disease. Thromb. Haemost. 117, 1528\u20131533 (2017).","journal-title":"Thromb. Haemost."},{"key":"82747_CR26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1046\/j.1365-2516.2001.00096.x","volume":"7","author":"BM Ewenstein","year":"2001","unstructured":"Ewenstein, B. M. Use of ristocetin cofactor activity in the management of von Willebrand disease. Haemophilia 7, 10\u201315 (2001).","journal-title":"Haemophilia"},{"key":"82747_CR27","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1055\/s-0038-1657727","volume":"78","author":"PJ Murdock","year":"1997","unstructured":"Murdock, P. J., Woodhams, B. J., Matthews, K. B., Pasi, K. J. & von Goodall, A. H. Willebrand factor activity detected in a monoclonal antibody-based ELISA: An alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use. Thromb. Haemost. 78, 1272\u20131277 (1997).","journal-title":"Thromb. Haemost."},{"key":"82747_CR28","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/j.1538-7836.2006.01715.x","volume":"4","author":"AO Spiel","year":"2006","unstructured":"Spiel, A. O., Mayr, F. B., Firbas, C., Quehenberger, P. & Jilma, B. Validation of rotation thrombelastography in a model of systemic activation of fibrinolysis and coagulation in humans. J. Thromb. Haemostas. JTH 4, 411\u2013416 (2006).","journal-title":"J. Thromb. Haemostas. JTH"},{"key":"82747_CR29","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1111\/jth.12194","volume":"11","author":"YV Sanders","year":"2013","unstructured":"Sanders, Y. V. et al. Reduced prevalence of arterial thrombosis in von Willebrand disease. J. Thromb. Haemostas. JTH 11, 845\u2013854 (2013).","journal-title":"J. Thromb. Haemostas. JTH"},{"key":"82747_CR30","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJMoa1800410","volume":"379","author":"SC Johnston","year":"2018","unstructured":"Johnston, S. C. et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N. Engl. J. Med. 379, 215\u2013225 (2018).","journal-title":"N. Engl. J. Med."},{"key":"82747_CR31","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMc1610341","volume":"375","author":"SC Johnston","year":"2016","unstructured":"Johnston, S. C. & Amarenco, P. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N. Engl. J. Med. 375, 1395 (2016).","journal-title":"N. Engl. J. Med."},{"key":"82747_CR32","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1056\/NEJMoa1916870","volume":"383","author":"SC Johnston","year":"2020","unstructured":"Johnston, S. C. et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N. Engl. J. Med. 383, 207\u2013217 (2020).","journal-title":"N. Engl. J. Med."},{"key":"82747_CR33","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1161\/STROKEAHA.111.616649","volume":"42","author":"HS Markus","year":"2011","unstructured":"Markus, H. S. et al. The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: A randomized trial. Stroke 42, 2149\u20132153 (2011).","journal-title":"Stroke"},{"key":"82747_CR34","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ejvs.2007.03.011","volume":"34","author":"GJ de Borst","year":"2007","unstructured":"de Borst, G. J. et al. Influence of antiplatelet therapy on cerebral micro-emboli after carotid endarterectomy using postoperative transcranial Doppler monitoring. Eur. J. Vasc. Endovasc. Surg. 34, 135\u2013142 (2007).","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"82747_CR35","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1055\/s-0038-1648251","volume":"118","author":"N Buchtele","year":"2018","unstructured":"Buchtele, N., Schwameis, M., Gilbert, J. C., Schorgenhofer, C. & Jilma, B. Targeting von Willebrand factor in ischaemic stroke: focus on clinical evidence. Thromb. Haemost. 118, 959\u2013978 (2018).","journal-title":"Thromb. Haemost."},{"key":"82747_CR36","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1055\/s-0038-1656120","volume":"77","author":"AJ Catto","year":"1997","unstructured":"Catto, A. J. et al. von Willebrand factor and factor VIII: C in acute cerebrovascular disease. Relationship to stroke subtype and mortality. Thromb. Haemostas. 77, 1104\u20131108 (1997).","journal-title":"Thromb. Haemostas."},{"key":"82747_CR37","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1111\/jth.13142","volume":"13","author":"CD Seaman","year":"2015","unstructured":"Seaman, C. D., Yabes, J., Comer, D. M. & Ragni, M. V. Does deficiency of von Willebrand factor protect against cardiovascular disease? Analysis of a national discharge register. J. Thromb. Haemost. JTH 13, 1999\u20132003 (2015).","journal-title":"J. Thromb. Haemost. JTH"},{"key":"82747_CR38","doi-asserted-by":"publisher","first-page":"11180","DOI":"10.1038\/s41598-020-68125-9","volume":"10","author":"KD Kovacevic","year":"2020","unstructured":"Kovacevic, K. D. et al. The aptamer BT200 effectively inhibits von Willebrand factor (VWF) dependent platelet function after stimulated VWF release by desmopressin or endotoxin. Sci. Rep. 10, 11180\u201311180 (2020).","journal-title":"Sci. Rep."},{"key":"82747_CR39","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1111\/jth.13696","volume":"15","author":"C Kawecki","year":"2017","unstructured":"Kawecki, C., Lenting, P. J. & von Denis, C. V. Willebrand factor and inflammation. J. Thromb. Haemost. JTH 15, 1285\u20131294 (2017).","journal-title":"J. Thromb. Haemost. JTH"},{"key":"82747_CR40","unstructured":"Van Mourik, J. & Romani, T. Von Willebrand Factor Propeptide in Vascular Disorders, (2001)."},{"key":"82747_CR41","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1160\/TH05-07-0527","volume":"95","author":"AD Blann","year":"2006","unstructured":"Blann, A. D. Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years. Thromb. Haemost. 95, 49\u201355 (2006).","journal-title":"Thromb. Haemost."},{"key":"82747_CR42","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1113\/jphysiol.2011.225417","volume":"590","author":"KY Stokes","year":"2012","unstructured":"Stokes, K. Y. & Granger, D. N. Platelets: A critical link between inflammation and microvascular dysfunction. J. Physiol. 590, 1023\u20131034 (2012).","journal-title":"J. Physiol."},{"key":"82747_CR43","doi-asserted-by":"publisher","first-page":"154157","DOI":"10.1016\/j.cyto.2017.09.013","volume":"122","author":"C Bakogiannis","year":"2019","unstructured":"Bakogiannis, C., Sachse, M., Stamatelopoulos, K. & Stellos, K. Platelet-derived chemokines in inflammation and atherosclerosis. Cytokine 122, 154157 (2019).","journal-title":"Cytokine"},{"issue":"Suppl 1","key":"82747_CR44","first-page":"S13","volume":"105","author":"AT Nurden","year":"2011","unstructured":"Nurden, A. T. Platelets, inflammation and tissue regeneration. Thromb. Haemost. 105(Suppl 1), S13-33 (2011).","journal-title":"Thromb. Haemost."},{"key":"82747_CR45","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1177\/000331979504600810","volume":"46","author":"G Gleerup","year":"1995","unstructured":"Gleerup, G. & Winther, K. The effect of ageing on platelet function and fibrinolytic activity. Angiology 46, 715\u2013718 (1995).","journal-title":"Angiology"},{"key":"82747_CR46","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1042\/cs0730507","volume":"73","author":"PB Davis","year":"1987","unstructured":"Davis, P. B. & Silski, C. Ageing and the alpha 2-adrenergic system of the platelet. Clin. Sci. 73, 507\u2013513 (1987).","journal-title":"Clin. Sci."},{"key":"82747_CR47","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s00335-016-9629-8","volume":"27","author":"CI Jones","year":"2016","unstructured":"Jones, C. I. Platelet function and ageing. Mammal. Genome 27, 358\u2013366 (2016).","journal-title":"Mammal. Genome"},{"key":"82747_CR48","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1161\/STROKEAHA.118.023954","volume":"50","author":"DG Hackam","year":"2019","unstructured":"Hackam, D. G. & Spence, J. D. Antiplatelet therapy in ischemic stroke and transient ischemic attack. Stroke 50, 773\u2013778 (2019).","journal-title":"Stroke"},{"key":"82747_CR49","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1160\/TH11-12-0867","volume":"107","author":"L Totani","year":"2012","unstructured":"Totani, L. et al. Prasugrel inhibits platelet-leukocyte interaction and reduces inflammatory markers in a model of endotoxic shock in the mouse. Thromb. Haemost. 107, 1130\u20131140 (2012).","journal-title":"Thromb. Haemost."},{"key":"82747_CR50","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1160\/TH05-01-0020","volume":"94","author":"V Evangelista","year":"2005","unstructured":"Evangelista, V. et al. Clopidogrel inhibits platelet-leukocyte adhesion and platelet-dependent leukocyte activation. Thromb. Haemost. 94, 568\u2013577 (2005).","journal-title":"Thromb. Haemost."},{"key":"82747_CR51","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.atherosclerosis.2020.04.018","volume":"307","author":"WC Schrottmaier","year":"2020","unstructured":"Schrottmaier, W. C., Mussbacher, M., Salzmann, M. & Assinger, A. Platelet-leukocyte interplay during vascular disease. Atherosclerosis 307, 109\u2013120 (2020).","journal-title":"Atherosclerosis"},{"key":"82747_CR52","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1161\/ATVBAHA.111.237529","volume":"32","author":"JM Siller-Matula","year":"2012","unstructured":"Siller-Matula, J. M. et al. ARC15105 is a potent antagonist of von Willebrand factor mediated platelet activation and adhesion. Arterioscler. Thromb. Vasc. Biol. 32, 902\u2013909 (2012).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"82747_CR53","doi-asserted-by":"crossref","unstructured":"Kovacevic, K.D., et al. von Willebrand factor predicts mortality in ACS patients treated with potent P2Y12 antagonists and is inhibited by aptamer BT200 ex vivo. Thromb. Haemost. (2020).","DOI":"10.1055\/s-0040-1713888"},{"key":"82747_CR54","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1080\/17512433.2019.1607293","volume":"12","author":"ML Sargentini-Maier","year":"2019","unstructured":"Sargentini-Maier, M. L. et al. Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura. Exp. Rev. Clin. Pharmacol. 12, 537\u2013545 (2019).","journal-title":"Exp. Rev. Clin. Pharmacol."},{"key":"82747_CR55","doi-asserted-by":"crossref","unstructured":"Zhu, S., et al. Potent and rapid reversal of the von Willebrand Factor Inhibitor Aptamer BT200. J. Thromb. Haemost JTH (2020).","DOI":"10.1111\/jth.14822"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82747-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82747-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82747-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T03:17:25Z","timestamp":1670037445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82747-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,4]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["82747"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-82747-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,4]]},"assertion":[{"value":"13 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Bernd Jilma, Shuhao Zhu and James C. Gilbert are cofounders of Band Therapeutics, SZ and JCG are employees of and BJ a consultant to Guardian Therapeutics. All other authors declare that they have no relevant conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3092"}}